In patients classified as stage 3 by Ishikawa, surgery seemed to increase survival however, surgery-associated complications conversely decreased the survival of patients with stage 1 disease. The cumulative survival rate at 10 and 20 years was 84.3 and 70.4 %, respectively. Thirty-seven late deaths were observed and the major causes were congestive heart failure and anastomotic aneurysms. A serious long-term complication was anastomotic aneurysms with a cumulative incidence at 10 and 20 years of 7.8 and 14.8 %, respectively. There were 12 hospital deaths, and the remaining 98 patients were followed up from 10 months to 48.4 years (mean 21.6 years). Survival was compared with the reported results of medically treated patients according to Ishikawa’s prognostic classification. A retrospective review was performed on 110 consecutive patients with Takayasu’s arteritis who underwent surgical treatment at our single institution. However, the efficacy of surgery in relation to long-term survival of the patients remains to be evaluated. In Japan, dupilumab, as an add-on to background therapy, is economically dominant compared with benralizumab, and cost-effective versus mepolizumab.Īsthma Japan biologics cost-effectiveness dupilumab.Surgical interventions are performed to ameliorate the complications of Takayasu’s arteritis, which adversely affects life expectancy. Versus omalizumab, dupilumab was not cost-effective (ICER of ¥10,802,368 ).

At a willingness-to-pay (WTP) threshold of ¥5,000,000 per QALY gained, dupilumab was the dominant strategy (lower cost, increased QALYs) versus benralizumab, and cost-effective versus mepolizumab with an incremental cost-effectiveness ratio (ICER) of ¥1,010,921 (US$9,190, US$1 = ¥110). The base case results suggest that treatment with dupilumab leads to fewer severe exacerbations and increased life-years (LYs) and quality-adjusted LYs (QALYs) than benralizumab and mepolizumab. Inputs were informed by dupilumab clinical trials (VENTURE and QUEST trials), the literature, official Japanese sources and expert opinions. Dupilumab was compared with benralizumab and mepolizumab, and against omalizumab (as a hypothetical scenario). The objective of this study was to assess the cost-effectiveness of dupilumab, compared with other biologics, as add-on treatment to background therapy in patients aged ≥12 years with uncontrolled, persistent asthma in Japan.Ī life-time Markov cohort model was used to conduct cost-effectiveness analysis from the Japanese healthcare payer perspective with an annual discount rate of 2%. Dupilumab is a first-in-class, monoclonal antibody for the treatment of atopic diseases, including persistent asthma. Asthma is a common, chronic inflammatory airway disorder, with up to 1,177,000 people receiving asthma treatment in Japan.

Miyata 110 value